Biosimilar Guidances: Broader Populations Permitted; More Immunogenicity Requested
New draft Q&A and three final guidances from FDA offer pros and cons for sponsors of biosimilar applications.
New draft Q&A and three final guidances from FDA offer pros and cons for sponsors of biosimilar applications.